IDENTIFICATION OF E. COLI O157 IN A BOVINE MILK FARM BY MULTIPLEX REAL-TIME PCR

Law provisions about direct sell of raw bovine milk require VTEC O157 monitoring in bovine milk farms (milk and faeces). It has been showed that culture-based methods used for this scope, besides being cumbersome and time-consuming, may be also less sensitive, compared to molecular approaches. In this study, a multiplex Real-Time PCR, able to identify VTEC O157, Salmonella spp and Listeria monocytogenes, has been used to analyse milk, filter, sewage and stool samples from a milk farm, in comparison with standard OIE methods. The performances of the molecular protocol have been preliminary assessed with lyophilized samples from proficiency testing VLA, showing 100% accordance. Results from field samples indicated the absence of the pathogen in milk, and the higher sensitivity of Real-Time PCR with other matrices, suggesting its potential use for fast VTEC O157 identification

The RainBO Platform for Enhancing Urban Resilience to Floods: An Ecient Tool for Planning and Emergency Phases

Many urban areas face an increasing flood risk, which includes the risk of flash floods. Increasing extreme precipitation events will likely lead to greater human and economic losses unless reliable and efficient early warning systems (EWS) along with other adaptation actions are put in place in urban areas. The challenge is in the integration and analysis in time and space of the environmental, meteorological, and territorial data from multiple sources needed to build up EWS able to provide efficient contribution to increase the resilience of vulnerable and exposed urban communities to flooding. Efficient EWS contribute to the preparedness phase of the disaster cycle but could also be relevant in the planning of the emergency phase. The RainBO Life project addressed this matter, focusing on the improvement of knowledge, methods, and tools for the monitoring and forecast of extreme precipitation events and the assessment of the associated flood risk for small and medium watercourses in urban areas. To put this into practice, RainBO developed a webGIS platform, which contributes to the “planning” of the management of river flood events through the use of detailed data and flood risk/vulnerability maps, and the “event management” with real-time monitoring/forecast of the events through the collection of observed data from real sensors, estimated/forecasted data from hydrologic models as well as qualitative data collected through a crowdsourcing app

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402